Loading...
NPI 1679226963 · Worth, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Sinai Laboratory Corp is a clinical medical laboratory provider located in Worth, Illinois. This profile covers 4 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Sinai Laboratory Corp |
| Address | 11111 S Harlem Ave |
| City | Worth |
| State | IL |
| ZIP | 60482 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 27, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $23.8M |
| Medicaid | $7.8K |
SINAI LABORATORY CORP is functionally a high-throughput clinical diagnostic operation focused on SARS-CoV-2 testing and associated specimen services: Medicare billing is dominated by molecular test codes 0240U (91.1K claims, $12.8M, 53.4% of Medicare revenue), U0003 (91.4K claims, $6.8M, 28.3%), and U0005 (91K claims, $2.3M, 9.5%), and the presence of G2023 (91.6K claims, $2.1M) further signals large-scale specimen collection activity rather than a broad multi-specialty lab mix.
Medicare revenue is highly concentrated: the top 3 Medicare codes account for 91.2% of total Medicare revenue, with total Medicare receipts of $23.8M. This concentration indicates the provider’s Medicare business is overwhelmingly dependent on a narrow set of COVID-19–related test services.
By contrast, Medicaid activity is negligible in scale relative to Medicare: lifetime Medicaid revenue is $7.8K versus $23.8M in Medicare, so the provider is effectively single-payer in commercial significance with Medicare driving virtually all lifetime reimbursement.
SINAI LABORATORY CORP is an outsized national operator for its principal Medicare codes: 0240U, U0003, and U0005 each rank #1 nationally for reported volume and are described as "extreme outlier" occurrences, placing the provider at the 100th percentile for those codes and indicating far-higher-than-typical national throughput for these assays.
State-level Medicaid positioning is modest and mixed. The top Medicaid codes (87426, G2023, 0240U) together account for 88.5% of the provider’s Medicaid revenue, yet ranks for those codes are typical or unremarkable in-state (87426 at the 45th percentile, G2023 at the 61st percentile), with 0240U somewhat higher in-state (rank 8 of 23, 68th percentile) but still representing very small absolute dollars.
Operational footprint implications: claim volumes reported (roughly 91K claims on multiple Medicare SARS-CoV-2 codes and 91.6K specimen-collection claims for G2023) imply a lab built for very large batch processing and high specimen throughput rather than small-volume clinical testing. The mix of high-volume PCR codes plus specimen-collection billing suggests centralized testing with extensive sample intake infrastructure.
Tenure and recency: the provider’s NPI was enumerated on 2022-01-27 (~4 years ago), indicating this high-volume testing profile emerged within a relatively recent enrollment window and concentrated quickly on pandemic-era test codes.
Statistical outlier characterization: for Medicare the leading lab codes are explicitly flagged as "extreme outlier" and the provider ranks at the top of national lists for 0240U, U0003, and U0005 — a clear indication that, for those services, this provider operates at a scale far above typical peers; by contrast, Medicaid code ranks are generally described as typical or unremarkable statewide, reinforcing that the provider’s exceptional scale is concentrated in Medicare (and the tests driving Medicare revenue).
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0240U | N/A | 91,120 | $140 | $12.8M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 91,430 | $70 | $6.8M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 90,970 | $30 | $2.3M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 91,570 | $20 | $2.1M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 90 | $30 | $3.1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,000 | $1 | $2K |
| 0240U | N/A | 900 | $1 | $1.8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 900 | $1 | $900 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 880 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 145 | 350 | 400 | $70 | $514.7K |
| 0240U | N/A | 8 | 20 | 240 | $120 | $403.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 97 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 154 | 400 | 550 | $20 | $90.8K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 495 | 910 | 110 | $30 | $14.4K |
Other providers in the same ZIP code as Sinai Laboratory Corp, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Mark Colander | IL | Optometrist | $28.2K | $4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.